Foghorn Therapeutics's three largest insider shareholders as of April 17, 2026 are Adrian Gottschalk (Chief Executive Officer, 511.70K shares), Adrian Gottschalk (Chief Executive Officer, 511.70K shares), Adrian Gottschalk (Chief Executive Officer, 511.70K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Adrian Gottschalk | Chief Executive Officer | 0 | 511,704 | 28 Apr, 2025 |
| Adrian Gottschalk | Chief Executive Officer | 0 | 511,704 | 13 Apr, 2026 |
| Adrian Gottschalk | Chief Executive Officer | 0 | 511,704 | 28 Apr, 2025 |
| Carl Decicco | Chief Scientific Officer | 362,707 | 0 | 13 Dec, 2021 |
| Cigall Kadoch | - | 295,000 | 0 | 15 Dec, 2021 |
| Cigall Kadoch | - | 295,000 | 0 | 15 Dec, 2021 |
| Steven F. Bellon | Chief Scientific Officer | 101,957 | 0 | 11 Sep, 2024 |
| Fanny Cavalie | Chief Strategy/Bus Ops Officer | 75,992 | 0 | 12 Mar, 2024 |
| Allan Reine | Chief Financial Officer | 53,784 | 0 | 11 Aug, 2021 |
| Allan Reine | Chief Financial Officer | 53,784 | 0 | 11 Aug, 2021 |
| Simba Gill | - | 34,061 | 0 | 14 Sep, 2022 |
| Simba Gill | - | 34,061 | 0 | 14 Sep, 2022 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 09 Apr, 2026 | Adrian Gottschalk | Common Stock | D | 47,497 | $0.00 | 0 | I | G |
| 09 Apr, 2026 | Adrian Gottschalk | Common Stock | A | 47,497 | $0.00 | 211,704 | I | G |
| 10 Apr, 2026 | Adrian Gottschalk | Common Stock | D | 59,208 | $0.00 | 240,792 | I | G |
| 10 Apr, 2026 | Adrian Gottschalk | Common Stock | A | 59,208 | $0.00 | 270,912 | I | G |
| 23 Feb, 2026 | Ryan D Maynard | Stock Option (right to buy) | A | 400,000 | $5.75 | 400,000 | D | A |
| 05 Feb, 2026 | Adrian Gottschalk | Stock option (right to buy) | A | 1,075,000 | $5.23 | 1,075,000 | D | A |
| 30 Jan, 2026 | Michael Lacascia | Stock option (right to buy) | A | 295,000 | $5.71 | 295,000 | D | A |
| 30 Jan, 2026 | Alfonso Quintas Cardama | Stock option (right to buy) | A | 300,000 | $5.71 | 300,000 | D | A |
| 30 Jan, 2026 | Anna Rivkin | Stock option (right to buy) | A | 165,000 | $5.71 | 165,000 | D | A |
| 30 Jan, 2026 | Steven F. Bellon | Stock Option (right to buy) | A | 300,000 | $5.71 | 300,000 | D | A |
| 30 Jan, 2026 | Carlos Costa | Stock option (right to buy) | A | 230,000 | $5.71 | 230,000 | D | A |
| 13 Jan, 2026 | Pioneering, Llc Flagship | Pre-Funded Warrants to purchase Common Stock | A | 2,235,468 | $6.71 | 2,235,468 | I | A |
| 13 Jan, 2026 | Pioneering, Llc Flagship | Series 1 Warrants to purchase Common Stock | A | 1,117,734 | - | 1,117,734 | I | A |
| 13 Jan, 2026 | Pioneering, Llc Flagship | Series 2 Warrants to purchase Common Stock | A | 1,117,734 | - | 1,117,734 | I | A |
| 17 Jun, 2025 | Michael Mendelsohn | Stock Option (right to buy) | A | 25,000 | $4.79 | 25,000 | D | A |
| 17 Jun, 2025 | B Lynne Parshall | Stock Option (right to buy) | A | 25,000 | $4.79 | 25,000 | D | A |
| 17 Jun, 2025 | Thomas J. Jr. Lynch | Stock Option (right to buy) | A | 25,000 | $4.79 | 25,000 | D | A |
| 17 Jun, 2025 | Ian F Smith | Stock Option (right to buy) | A | 25,000 | $4.79 | 25,000 | D | A |
| 17 Jun, 2025 | Scott Biller | Stock Option (right to buy) | A | 25,000 | $4.79 | 25,000 | D | A |
| 17 Jun, 2025 | Douglas G. Cole | Stock Option (right to buy) | A | 25,000 | $4.79 | 25,000 | D | A |